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The international drug control system is stoking 
a global crisis of inequitable access to controlled 
medicines. Of the global population, an estimated 
5.5 billion have poor to nonexistent access to opioid 
analgesics, in particular morphine, resulting in the 
avoidable pain and suffering of people around the 
world. At the last estimate, 92 percent of the world’s 
supply of morphine was consumed by just 17 percent 
of the global population, that consumption primarily 
concentrated in the global north.
Terminal cancer patients, end-stage AIDS patients, 
and women in labor suffering from uncontrolled pain 
are among the key impacted groups, with the World 
Health Organization (WHO) estimating that tens of 
millions suffer from unrelieved pain annually due to 
a lack of access to controlled medicines. In addition, 
only a fraction of people globally who inject drugs are 
able to access controlled medicines for treating opioid 
dependence.
Under international drug control law and international 
human rights law, States have an obligation to ensure 
controlled medicines are made available to their 
populations; any restriction of access constitutes a 
violation of the right to health. Though a number 
of factors impose barriers to access, including 
weak healthcare systems and the lack of training of 
clinicians working on the ground, the international 
drug control system has been responsible for 
perpetuating the continual undersupply of controlled 
medicines. 
This scarcity is due to the prioritization, by 
governments and UN bodies alike, of preventing the 
diversion of controlled substances for illicit purposes 
over ensuring access for medical and scientific 
needs. For example, both the International Narcotics 
Control Board (INCB) and United Nations Office on 
Drugs and Crime (UNODC) have a dual obligation 
to maintain a balance between preventing diversion 
and ensuring access, yet have historically favored the 
former. This has translated to the national level where 
some governments continually emphasize a criminal 
justice approach to drug control, rather than a public 
health one, all to the detriment of providing access to 
controlled medicines.
In some countries, overly burdensome regulations 
for prescribing controlled medicines, something that 
can be linked to the UN drug conventions, create a 
situation where physicians must operate in a climate 
of fear and legal uncertainty, real or perceived. As 
a result, many are afraid of prescribing controlled 
medicines due to the risk of prosecution, or of being 
charged with professional misconduct for failing 
to adhere to stringent regimes. What’s more, this 
environment contributes heavily to broader societal 
attitudes and the stigmatization of people who use 
controlled substances, licit or otherwise.
The INCB and UNODC have begun to take steps to 
rectify this gross inequity of access around the world, 
and WHO’s increasing involvement in the issue over 
the past decade is a key step in the right direction. 
However, there is considerable work to do to amend 
the damage caused by decades of placing a primacy 
on anti-diversion measures in drug control. 
With an increasing number of States and UN 
bodies drawing attention to the lack of access to 
controlled medicines, we are reaching a critical 
juncture, particularly with the United Nations General 
Assembly Special Session on drugs approaching in 
2016. The time for concrete action on the issue is now. 
A new global initiative must be explored and greater 
power and funds must be handed to WHO, to lead on 
tackling inequitable access to controlled medicines. 
Without action, millions of people will continue to 
suffer unnecessarily. 
EXECUTIVE SUMMARY
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RECOMMENDATIONS
1 States and UN bodies must utilize the United Nations General Assembly 
Special Session (UNGASS) on drugs in 2016, to both acknowledge and 
begin to forcefully address the major gap in access to controlled medicines, 
particularly opioids for pain relief. More than 75 percent of the world’s 
population has little or no access to such medicines, leading to the avoidable 
pain and suffering of millions. There must be an admission that the 
international drug control system represents a barrier to accessing controlled 
medicines. 
2 States must recognize they have an obligation under international law to 
ensure access to controlled medicines for their populations. This obligation is 
implied in the cornerstone treaty of the international drug control system, the 
Single Convention on Narcotic Drugs, and is firmly rooted in the right to the 
highest attainable standard of health in international human rights law. 
3 UN drug control bodies and States must recognize that drug policies at both 
national and international levels are imbalanced, with emphasis on preventing 
diversion of controlled substances holding primacy over ensuring their access 
for medical use. This has profound implications for public health and human 
rights around the world. 
4 A high priority must be given to the treatment of physical and mental pain 
by ensuring access to controlled medicines, including opiates, for pain relief, 
palliative care, anesthesia, dependency, and all other forms of suffering. 
While States have the obligation to ensure the production and/or import of 
sufficient quantities of such medicines—especially those that are on WHO’s 
Model List of Essential Medicines—WHO, UNODC, and INCB must provide 
governments with the necessary technical and financial support. 
5 Governments should provide the necessary funding for a renewed 
international program to be overseen by WHO, in partnership with UNODC 
and the INCB, to ensure adequate and affordable access to controlled 
medicines where they are unavailable. 
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76 Priority must be given to expanding the spectrum of treatment for opioid 
dependence, while respecting human dignity and offering the possibility of 
prescription of controlled medicines such as methadone and buprenorphine 
(included in WHO’s Model List of Essential Medicines) or diamorphine. This 
can be done in line with the WHO-UNODC-UNAIDS Technical Guide: for 
countries to set targets for universal access to HIV prevention, treatment and 
care for injecting drug users. States and the relevant UN bodies must work 
together to address the failure of many countries to adequately implement 
opioid substitution therapy (OST) for opioid-dependent people. 
7 Governments should establish clear plans to remove the barriers to ensuring 
access to controlled medicines, including: national drug policies anchored 
in a criminal justice approach, rather than a public health and human rights 
approach; burdensome domestic regulatory frameworks; stigmatized societal 
attitudes driving a fear of prescribing opioids for pain relief and the treatment 
of opioid dependence; poor knowledge of these medicines by health 
professionals and regulators; and overpricing. 
8 The INCB must take more assertive steps in working with countries that 
consistently fail to ensure adequate access to controlled medicines, and should 
work increasingly with governments and national health authorities to ensure 
they provide evidence-based estimates of the need for controlled medicines. 
9 Governments and UN drug control bodies should acknowledge and address 
the gaps and lost opportunities in relation to the medical use of, and medical 
research into, controlled substances, including cannabis. They should review 
the 1961 and 1971 drug conventions’ schedules in light of scientific evidence 
and prioritize exploring the medical benefits of controlled substances, based 
on WHO’s Expert Committee on Drug Dependence recommendations.  
10 The United Nations and the international community must urgently address 
inadequate access to controlled medicines as a global health priority. Demand 
for these medicines is driven not by political expediencies, but by the universal 
human susceptibility to illness and pain. It is not acceptable to wait for a 
consensus from States on broader drug policy reform. It is time for action. 
© WHO/EURO/Gilles Reboux
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Medicines made of or containing opioids are essential, 
not only in the treatment of pain, but also in treating 
opioid dependence. Methadone and buprenorphine 
are primarily used in opioid substitution therapy 
(OST), a medical treatment for people suffering from 
opioid dependence, and are both controlled under 
the UN drug treaties.4 These, along with morphine, 
are included in the WHO’s Model List of Essential 
Medicines,5 which serves as the key guide for 
national governments and institutions in determining 
what medicines they should make available in their 
healthcare systems.
The Single Convention affirms in its preamble that 
the medical use of substances controlled under the 
treaty “continues to be indispensable for the relief 
of pain and suffering,” and that “adequate provision 
must be made” to ensure their availability.6 Yet, many 
countries have failed to fulfill this objective. Instead, 
fears over the dependency on controlled opioids and 
their diversion into the illicit market have trumped 
concerns for their medical availability. This is despite 
the fact that research, while limited, has shown that 
among patients with no history of substance misuse 
who were treated with opioid analgesics, only 0.43% 
misused their medication, while just 0.05% developed 
dependence.7
In the United States, the world’s largest consumer of 
opioid analgesics, there has been alarm about the rise 
in deaths from 1999 to 2011 related to their misuse,8 
which may suggest that widespread availability 
contributes to misuse. However, recent research into 
this trend has found that the only common predictor 
of pain relief medication misuse is past-year illicit drug 
use disorder.9 These findings underscore that if there 
is no history of substance misuse then the likelihood 
of developing dependence or misusing opioid 
analgesics will be low.
Sadly, this means that patients with a history of drug 
use or misuse often find it difficult to access opioid 
pain relief medications, partly as a result of the fear 
that they are more susceptible to developing 
dependence. This fear should never be a reason for 
withholding treatment and opioid analgesics should 
be prescribed when there is a clinical need.10
There is an urgent need 
to ensure greater access 
to controlled medicines 
around the world 
The international drug control system is stoking 
a global crisis of inequitable access to controlled 
medicines, resulting in the avoidable pain and 
suffering of people around the world. Controlled 
medicines are used in fields as diverse as neurology, 
psychiatry, and anesthesia. This report will examine 
in depth the situation as it pertains to access for the 
treatment of pain and opioid dependence. 
An estimated 5.5 billion people—over 75 percent 
of the global population—have low to nonexistent 
access to opioid analgesics,2 which are controlled 
under the cornerstone treaty of the drug control 
system, the 1961 United Nations (UN) Single 
Convention on Narcotic Drugs (Single Convention). In 
the case of morphine, one of the most vital analgesics 
for treating moderate-to-severe pain, 92 percent of 
the world’s supply is consumed by just 17 percent of 
the world’s population, that consumption primarily 
concentrated in the global north. As of 2014, strong 
opioids and opiates were virtually unavailable in over 
150 countries.3
EUROPE (11%) 22.5%
CANADA (0.5%) 7.7%
AUSTRALIA AND NEW ZEALAND (0.4%) 2.5%
JAPAN (2%) 0.5%
OTHER COUNTRIES (81.1%) 9.5%
UNITED STATES (5%) 57.3 %
FIGURE 1:
MORPHINE: 
DISTRIBUTION OF CONSUMPTION 2013
Note: Percentages in parentheses  refer to share of the world population 
(i.e. total poulation of all reporting countries).     
Source: INCB
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The lack of access to controlled 
medicines has created a 
public health and human 
rights crisis, resulting in 
the suffering of millions 
Pain relief through the use of controlled medicines is 
an essential component of medical care for a number 
of groups, among them: terminal cancer patients, 
women in labor suffering from uncontrolled pain, 
end-stage AIDS patients in pain, and people suffering 
injuries caused by accidents or violence. More than 
two-thirds of cancer patients and half of patients with 
advanced HIV/AIDS,11 including many who either 
have no access to antiretroviral treatment (ART) or 
access it very late, will experience moderate-to-severe 
pain. Pain relief may also be required during labor, or 
in surgery and post-surgery settings. 
WHO estimates that each year tens of millions of 
people suffer from unrelieved pain arising from a 
lack of access to controlled medicines,12 in particular 
opioids. 
Access to palliative care—a medical specialty that 
seeks to alleviate suffering and improve quality of 
life for people with life-limiting illnesses—and opioid 
analgesics is of particular importance for cancer 
patients in low- and middle-income countries, as 
they are often diagnosed when the disease is in 
its advanced stages,13 or may not have access to 
chemotherapy and radiotherapy because of weak 
healthcare infrastructure.14 The lack of palliative care 
services on offer in these countries means that nine 
out of 10 people around the world in need of such 
care are not receiving it.15
The severe deficit in the availability and access to 
pain relief medicines has broader physical, societal, 
and economic implications than the immediate failure 
to alleviate suffering; for example, patients deprived 
of access to controlled medicines can suffer from a 
subsequent loss of strength and mobility.16 In terms 
of social and economic impacts, failure to secure 
access to pain relief medication can result in the future 
inability to work or care for children properly, and 
cause undue distress for family members. In certain 
severe cases, some patients deprived of controlled 
medicines for pain relief have resorted to taking their 
own lives.17
There are additional benefits that can be derived from 
administering opioid analgesics beyond pain relief. At 
the 2015 World Health Assembly, Australia’s Chief 
Medical Officer, Professor Chris Baggoley, shared his 
professional experience, highlighting that providing 
pain relief “not only gave comfort to…patients but it 
also expedited the ability to more accurately and more 
quickly diagnose and treat their afflictions.”
What are essential controlled medicines?
Substances controlled under international law are routinely used in healthcare in such 
diverse fields of medicine as analgesia, anesthesia, drug dependence, maternal health, 
mental health, neurology, and palliative care. The World Health Organization (WHO) has 
included twelve medicines that contain internationally controlled substances in its Model List 
of Essential Medicines; these medicines should be available to anyone who needs them.
“The evidence is clear: around the world, we see that countries which integrate public 
health into drug control work achieve greater health effects and greater social benefits, 
while at the same time indeed improving the rule of law and security. Our priority 
must be to promote health-based responses which offer care for drug users. We must 
ensure access to essential controlled substances for legitimate medical purposes.”1
Jan Eliasson, UN Deputy Secretary-General, 2015 
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Inadequate access to controlled medicines and the 
ensuing public health implications are not limited to 
pain relief; OST for treating opioid dependence is only 
available in 80 countries and territories.18 Worse still, 
recent global estimates suggest that just 6–12 percent 
of people who inject drugs receive OST,19 despite 
the proven efficacy of this treatment in curtailing the 
spread of HIV and hepatitis C.
In spite of medical advances over the past century, no 
alternatives to strong opioids for treating moderate-
to-severe pain have been found so far. This underlines 
the importance of scaling up their global provision to 
tackle the inexcusable suffering of some of the most 
vulnerable populations. The international community 
has the capacity to overcome the serious deficit in 
availability of medicinal opioids throughout the globe, 
yet has to date been unable to because of myriad 
factors. While acknowledging the importance of these 
dynamics, this report explores the international drug 
control system’s role in limiting access to controlled 
medicines and the undue focus on upholding 
components of it that frequently contravene human 
rights recognized in international law. 
States have an obligation under 
international law to ensure 
access to controlled medicines 
As stated in its preamble, the Single Convention 
promotes access to controlled medicines, recognizing 
that “adequate provision must be made to ensure the 
availability of narcotic drugs for [medical] purposes.”20 
This principle is operationalized within the treaty 
through the creation of obligations and mechanisms 
designed to ensure that adequate supplies of 
controlled medicines are available to States.
The preamble of the Single Convention implies an 
obligation not only to have supplies of controlled 
medicines available to States, but also for States to 
make those medicines available to their populations. 
This implied obligation within international drug 
control law is explicit within international human rights 
law: the UN Committee on Economic, Social and 
Cultural Rights has clarified that access to “essential 
drugs” is an element of the right to the highest 
attainable standard of physical and mental health 
(hereinafter “the right to health”) under Article 12 
of the International Covenant on Economic, Social 
and Cultural Rights (ICESCR).21  Under the right 
to health framework, first articulated in the 1946 
Constitution of the WHO,22  States Parties have a 
clear obligation to ensure the realization of the right 
to health,23 including making medicines available. 
This includes those which may also be substances 
controlled pursuant to the drug control conventions 
and national laws implementing those conventions; 
the fact that a substance is scheduled under a drug 
control convention does not oust a state’s obligations 
to ensure access to it for medical purposes.
Indeed, the obligations under the Single Convention 
and the ICESCR are complementary and mutually 
reinforcing.24 However, these obligations are not 
being met by far too many States, thus violating the 
right to health and providing an example of rights 
abuses being perpetuated in the name of drug control.
Such abuses are well documented, from forced 
detention in so-called rehabilitation centers,25 
which offer little in the way of medical care for drug 
treatment (and are replete with other forms of torture 
or other cruel treatment),26 to continued use of the 
death penalty for drug offenses, a sanction that 
violates international law.27 The Single Convention, 
though expressing in its preamble a concern for the 
“health and welfare of mankind,” has been criticized 
for failing to include mention of the 1948 Universal 
Declaration of Human Rights—an absence that 
has in part allowed drug control to supersede the 
human rights obligations of States.28 Indeed, this is 
exacerbated by Article 39 of the Single Convention, 
which allows States to “adopt measures of control 
more strict or severe than those provided by the 
Convention.”29
Observers and UN bodies alike have continually 
highlighted the clear violation of human rights 
in restricting access to controlled medicines, yet 
to little avail. In 2008, for example, two Special 
Rapporteurs appointed by the UN Human Rights 
Council sent a joint letter to the Commission on 
Narcotic Drugs (CND),30  the policy-making body of 
the United Nations on drug control issues, reminding 
governments of their “minimum core obligations 
under the right to health” to provide controlled 
medicines, and called for the issue of lack of access 
to be “addressed forcefully in the next ten-year 
drug strategy.”31Progress, however, while made 
incrementally in the years since 2008 by some States, 
has been slow to nonexistent in many countries.
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The international drug control system does not 
operate outside of international human rights law. 
Rather, these legal regimes operate concurrently, 
as part of a broad range of international legal 
commitments.  Therefore, fulfilment of State 
obligations under the drug treaties must be done in 
conformity with these concomitant human rights 
obligations.32 
The International Narcotics Control Board (INCB), 
the body of independent experts established to 
monitor the three international drug control treaties, 
has continually defended the drug conventions 
as being compliant with human rights norms, and 
recommended that States give “due consideration” 
to both human rights norms and their obligation to 
ensure access to controlled medicines.33 However, 
such language lacks the force it should carry in 
ensuring States comply with their obligations under 
international law, and is at the heart of the problems 
with the international drug control system and those 
tasked with upholding it: the implicit prioritization of 
restricting availability, rather than ensuring access for 
public health purposes.
The international drug control 
system contains a “deep-lying 
imbalance” that favours punitive 
approaches over ensuring 
access to controlled medicines 
In practice, drug control law has made promoting 
access to controlled medicines a secondary 
consideration to that of preventing the diversion of 
these substances.36 During the drafting process of the 
Single Convention, much of the focus was on tackling 
the illicit trade in narcotics and “addiction,” described 
A dangerous precedent: the move to bring ketamine under international control
Ketamine, a substance on the WHO’s Model List of Essential Medicines, is the only available 
anesthetic for essential surgery in most rural areas of low- and middle-income countries, 
home to more than 2 billion people.34 Unlike other essential medicines discussed in this 
report, it is not controlled under the UN drug conventions. However, ahead of the 58th 
Session of the CND in 2015, China—concerned about domestic misuse of the drug—pushed 
for ketamine to be controlled under the 1971 Convention on Psychotropic Substances.
Bringing ketamine under international control, as opioids are, would create a 
public health and human rights crisis that would reverberate throughout many 
developing countries. The WHO Expert Committee on Drug Dependence (ECDD) 
has recommended on three separate occasions—2006, 2012 and 2014—that the 
CND not bring ketamine under international control, noting in its 2014 review that 
scheduling “would limit access to essential and emergency surgery…in countries 
where no affordable alternative anesthetic is available.”35 China finally withdrew 
its proposal and a CND vote on the issue has, at least for now, been delayed. 
The fact that a vote could still take place, however, is of concern. Firstly, if a decision 
were taken to control ketamine, this would perpetuate the imbalance in the UN 
drug treaties, allowing fears of misuse and prioritization of preventing diversion to 
supersede much-needed access for medical and scientific purposes. Secondly, the 
refusal by certain States to properly consider WHO’s recommendations on ketamine 
sets a worrying precedent, highlighting the need for issues of global access to essential 
medicines—controlled or otherwise—to be placed firmly within the mandate of WHO.
12GLOBAL COMMISSION ON DRUG POLICY:  Drug Control’s Negative Impact on Public Health: The Global Crisis of Avoidable Pain
in the preamble of the Single Convention as “a serious 
evil.” This focus on preventing diversion is evident 
in the treaty obligations requiring States to penalize 
various acts, including the cultivation, manufacture, 
sale, and possession of controlled substances. 
Conversely, specific provisions such as these are 
conspicuously absent when it comes to ensuring 
access to controlled medicines. Thus, there is “a deep-
lying imbalance in the text [of the Convention].”37 
Recognition from UN drug control bodies of this 
imbalance, and of their implicit roles in propagating 
it, has been seriously lacking, as have been efforts 
to address it. For one, the CND has historically been 
inactive on the issue of access, with resolutions on 
promoting adequate availability not adopted until 
2010 and 2011.38 While these were certainly welcome 
steps, the decades of silence on the matter highlight 
the ingrained prioritization of drug control elements 
within the conventions. 
With regards to the 2011 resolution, the United 
Nations Office on Drugs and Crime (UNODC) was 
requested to review, and update where necessary, 
its model laws to ensure that the appropriate balance 
between ensuring access and preventing diversion 
is achieved. These laws had been described as 
“excessively stringent” and criticized for failing to 
provide sufficient focus on encouraging domestic 
laws to ensure access.39 Revision of the UNODC’s 
model legislation on drug control is thus welcome; 
yet, four years after the CND’s request, it is still to 
be finalized and there is concern that the proposed 
amendments—based on indications during the 
drafting process—may not address previous failings. 
This ultimately leaves a considerable void in the 
provision of assistance to States in implementing 
balanced domestic laws.
When it comes to the INCB, since 1989 the body 
has played an important part in highlighting the lack 
of availability of controlled medicines; however, 
its statements have not been matched by concrete 
actions to alleviate the problem. The INCB has often 
placed the onus solely on national governments for 
failing to ensure access, doing so in isolation from a 
critique of the barriers created by the international 
drug control system as a whole. Thus, there has been 
a failure to acknowledge its role in perpetuating the 
imbalanced focus through an historical prioritization 
of law enforcement and drug control.40 The 
emphasis placed by many national governments on 
overregulation stems from the very prohibitionist 
elements instilled in them by the Single Convention 
and key UN bodies.
At the operational level, the INCB has failed to 
adequately use its influence to reduce systemic 
barriers contained within the Single Convention. The 
principal obstacle here is the “estimates” system the 
INCB manages, whereby countries are required to 
submit annual figures on their needs for controlled 
substances for scientific and medical purposes, before 
they can import. (This system will be critiqued later in 
the report.)
The INCB’s record on drawing international attention 
to the issue is commendable. However, it is failing to 
use its influence maximally to promote an effective, 
balanced approach and as such has contributed to 
the many barriers that exist in ensuring the adequate 
availability of controlled medicines.
Access to controlled medicines 
is seriously hindered by 
a number of key factors 
alongside the international 
drug control system 
In addition to the international drug control system, 
there are a number of other factors that significantly 
impede access to controlled medicines. Weak 
healthcare systems that lack funding and resources 
are a fundamental problem, inevitably impacting the 
availability of controlled medicines. 
Furthermore, the lack of clinical education and 
training for health professionals is a serious obstacle 
to the proper provision of controlled medicines, in 
particular opioid analgesics. Millions of physicians, 
nurses, pharmacists, and drug control officials have 
little understanding about, or formal training in, pain 
management or palliative care. The World Health 
Assembly’s Resolution WHA 67.19 acknowledged 
this gap and recommended that States scale-up the 
training of health professionals in relation to palliative 
care and those working with patients with life-
threatening conditions; this includes ensuring access 
to controlled medicines for pain management.41
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Pain Free Hospital Initiative in Kenya
“Pain is real and I will not fear morphine if my patient is in severe pain,” was the comment 
of one health worker attending Kenya’s Pain Free Hospital Initiative (PFHI). Kenya is a 
country that has made significant efforts to scale-up access to opioid analgesics. 
The PFHI addresses the knowledge and training gap through an education course aimed 
at patients and staff. This course aims to ensure that clinicians receive regular training 
sessions to assist them in their knowledge of pain management. In addition, the program 
makes sure that there is an adequate supply of controlled medicines for pain relief.42
Many of these impediments cannot be seen in 
strict isolation of a country’s drug laws as they are 
in part influenced by the fact that the use and/or 
possession of illicit versions of controlled medicines 
are criminalized in most countries. This conflation 
of licit medicinal products with illicit substances 
contributes to an anti-drug environment where 
controlled medicines are demonized despite their 
necessity in healthcare settings. One explanation 
for this conflation may be that controlled medicines 
are categorized in certain countries as “poisons,”43 
or “dangerous drugs,”44 by the governmental bodies 
charged with controlling and dispensing them. 
This can influence the practices and view of health 
professionals, family members and patients, and 
can result in fear of prescribing, a family member 
withholding, or a patient refusing pain relief 
medication.45 
This ultimately feeds into the broader social attitudes 
that play a major role in limiting access. Patients, 
families, and prescribers are often reluctant for such 
medicines to be prescribed because of the stigma 
associated with their use and the fear that use will 
inevitably lead to dependency, despite evidence to 
the contrary.46
Finally, the pricing and procurement of controlled 
medicines, while a complex area to explore due to 
the many factors contributing to high prices for what 
are ostensibly cheap medicines, has proven to be an 
impediment, with countries with low consumption 
levels often facing the highest prices.47 Although 
morphine is off-patent, and cheap to manufacture and 
produce, national overregulation, burdensome and 
overly complicated import/export systems, lack of an 
assured market in countries where medical opioids are 
largely unavailable, and anticipated low profit margins 
result in high prices to consumers in countries that 
do not subsidize imports or produce the medicine 
themselves. In the Philippines, for example, one 
month’s supply of immediate-release oral morphine 
is the equivalent of one month’s salary at minimum 
wage.48 Although many governments subsidize 
Photo: Nyeri Hospice, part of KEHPCA, Kenya Hospices and Palliative Care Association. 
© Sven Torfinn for the Open Society Foundations
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Human Rights Watch: “All I can do is cry”:  
Cancer and the Struggle for Palliative Care in Armenia 
Armenia has one of the most restrictive prescribing regimes for opioids in Europe. Oral 
morphine is not available, with only injectable forms dispensed. Furthermore, use of 
such controlled medicines is limited to those who have cancer and whose diagnosis must 
be confirmed by biopsy. Only oncologists can issue a prescription and no prescription 
can be issued without the case being presented to a Standing Commission made up of 
numerous individuals, who will not agree to the dispensing of opioids until they have 
seen the patient in their own home. The prescription has to be stamped by four different 
agencies and will usually only provide enough opioids for 24–48 hours. In addition, 
prescribers are required to share their patient’s confidential details with the police, 
breaching a person’s right to privacy and their right to confidentiality, both of which 
are core principles of the right to health. The system leaves thousands of people in 
unnecessary pain and for those cancer patients who are entitled to access opioids, the 
burdensome nature means many die before they can access pain relief medication.57 
“A predominant focus on criminalizing drug use has resulted in severely limited 
access to, or a complete lack of, opiates in some States because of concerns they 
may be diverted for illicit uses….Failure to offer access to opiates for legitimate 
medical treatment is a violation of the right to health, and needs to be addressed 
as such in States that have eliminated, or severely limited, their use.”51
Navi Pillay, former High Commissioner for Human Rights, 2014
• In Georgia, pharmacies dispensing opioid medications are based in police 
stations where patients have to go to collect their medication.61 
•  Ten African countries limit prescriptions of opioid analgesics to no more 
than two weeks at a time; in Ghana specifically it is just two days.62 
15GLOBAL COMMISSION ON DRUG POLICY:  Drug Control’s Negative Impact on Public Health: The Global Crisis of Avoidable Pain
more expensive medications and formulations, only 
a few—those that have committed to the availability 
of controlled medicines for pain relief and palliative 
care—subsidize morphine imports and distribute the 
medicine themselves.49 
The Global Commission acknowledges that these 
factors are serious impediments to access, and 
encourages national governments and UN bodies 
to take a coordinated approach to overcome them. 
WHO’s Policy Guidelines for Controlled Substances, 
which provide direction for governments on 
policies and legislation with regards to availability, 
accessibility, and affordability,50and WHA Resolution 
67.19, should serve as resources in this process. 
Governments limit access to 
controlled medicines by taking 
a criminal justice approach 
rather than an evidence-
based, human rights-oriented 
public health approach 
For decades both the INCB and UNODC have 
provided very little comment on States’ failure to 
implement their legal obligation to ensure access to 
controlled medicines, rather focusing overwhelmingly 
on the duty to prevent diversion of substances for 
illicit purposes.52 This is evident in INCB’s annual 
reports and UNODC’s annual World Drug Report. 
The 2015 World Drug Report, for example, continues 
to frame the “world drug problem” solely as a matter 
of production, supply, and use of illicit substances, 
with the lack of access to controlled medicines being 
given only a fleeting mention in the preface.53 Of the 
12 World Drug Reports published since its inception 
in 2004, the issue of access to controlled medicines is 
absent in nine of them.
Only recently has the INCB begun to take steps 
to address the imbalance that exists, despite their 
mandate to monitor compliance with the dual 
obligation contained in the treaties of ensuring access 
and preventing diversion.54 In light of this historic 
disparity, many commentators have referred to a 
“lopsided” focus of the INCB, UNODC, CND, States, 
and to some degree the conventions themselves, 
where a concern over the medical use of certain 
controlled substances has been lacking.55 
It is against the backdrop of this imbalanced focus 
that national governments have implemented 
overly burdensome regulatory frameworks for the 
provision of controlled medications, with measures 
in many cases going beyond what is required in the 
international drug treaties.56 
National regulatory barriers vary greatly among 
nations and directly influence availability and 
accessibility to controlled medications, in particular 
opioid analgesics. These can include: 58 59 60 
• limits on the number of days’ supply that can be 
provided in a prescription; 
• limits on doses; 
• limitations on who can prescribe, with some 
countries only allowing certain classes of doctors 
to issue a prescription; 
• “special” procedures for prescribing opioids 
making the process more onerous, including 
“specific” forms that are difficult to obtain, or a 
requirement that multiple forms be completed; 
• patients either needing to “register” or “receive 
special permission” to ensure eligibility; 
• “excessive penalties” for prescription errors or 
“mishandling of opioids”; 
• limited number of pharmacies being able or 
willing to dispense opioids; 
• unreasonable storage requirements. 
These are both unacceptable and unnecessary 
practices creating an environment of fear for 
physicians, many being afraid of failing to adhere to 
such a stringent regime and thus risking prosecution. 
For patients, these highly restrictive practices can 
be exacerbated by other factors in low- and middle-
income countries such as living in a rural area where 
travel to a city for opioids is required and may not be 
possible due to a scarcity of money and/or transport.
A number of countries not only impose onerous 
conditions for the manufacture and distribution of 
controlled medicines but also subject license holders 
to harsh punishments even for minor breaches, such 
as in record keeping. As a result, pharmaceutical 
companies avoid dealing in controlled medicines, 
thereby limiting access for patients.
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Many States have national bodies appointed to 
oversee their dual obligation under the international 
drug treaties.  However, in a number of countries the 
imbalanced focus, stemming from the international 
drug control system, results in resources and 
personnel being concentrated on combating the illicit 
market in controlled substances. 
As these national bodies are overwhelmingly focused 
on managing all aspects of the trade in controlled 
substances through a criminal justice lens, States 
should establish a public health-focused body, under 
the control of the Ministry of Health or other relevant 
ministry, to take over the role of ensuring access to 
controlled medicines. International drug control and 
relevant UN bodies should aid this process through 
the promotion of an evidence-based public health 
model, with technical assistance provided by WHO 
and in-country or regional UNODC staff. States must 
ensure that their national laws are consistent with 
obligations under international law to uphold the right 
to health.
The global estimates system has 
failed to ensure adequate access 
to controlled medicines. The 
INCB must take further assertive 
steps to amend its deficiencies 
The imbalanced nature of the international drug 
control system comes to light in the operational 
paragraphs of the Single Convention that place 
an emphasis on acts to penalize and prohibit, 
while neglecting to provide specific guidance on 
how countries should ensure access to controlled 
medicines. The only provisions that deal with the 
latter principle are Articles 12, 19 and 20, and are 
related to the “estimates” system and the requirement 
to report consumption of controlled medicines.63
Many countries regularly submit estimates to the 
INCB that do not reflect their medical needs, while 
some do not submit figures at all. The system itself has 
failed to achieve the purpose of ensuring adequate 
supplies to States, as new annual estimates are often 
based on consumption of controlled medicines within 
the country the previous year, meaning low and 
inadequate provision continues in many countries. 
Historically, the INCB has not pressed governments 
FIGURE 2:
ADEQUACY OF OPIOID ANALGESIC CONSUMPTION (2010)
© WHO 2012
ADEQUATE
MODERATE
LOW
VERY LOW
NO CONSUMPTION
DATA NOT AVAILABLE
NOT APPLICABLE
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the 
World Health Organization concerning the legal status of any country, territory, city, or area or its authorities, or concerning the delimitation of its 
frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. Data source: WHO.
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sufficiently to scale-up their estimates in order to meet 
the obvious medical need, thus ensuring an endless 
cycle of underestimation. 
For example, 2006 figures on global consumption of 
morphine equivalents found that six times the actual 
amount consumed that year would be required to 
ensure adequate global supply.64  This striking deficit, 
while not prevalent to the same degree as 2006, 
persists today and must be addressed. 
The INCB, working with WHO, has taken steps to 
tackle this issue in recent years, in 2012 releasing its 
comprehensive Guide on Estimating Requirements 
for Substances under International Control.65 This 
publication intends to help the relevant national 
authorities better calculate and prepare estimates to 
submit to the INCB of controlled substances required 
for medical and scientific purposes. The Commission 
urges the INCB, in collaboration with WHO and 
UNODC, to continue to take assertive steps 
encouraging States to submit estimates that accurately 
reflect the medical need of their populations. If this 
action does not materialize, there is a very real risk 
that continuous underestimation will persist.
Treatment for opioid 
dependence with controlled 
medicines improves 
public health and is cost-
effective. Access to them 
must be scaled-up 
Methadone and buprenorphine are the most 
commonly used controlled medicines for OST and 
are included in the WHO’s Model List of Essential 
Medicines; however, some countries also provide 
alternatives such as slow-release morphine and 
codeine, or heroin-assisted treatment.
OST decreases or eliminates injecting practice among 
people who use drugs, thus significantly reducing HIV 
and hepatitis C transmission in this group, an outcome 
for which there is a well-established evidence 
base.66Based on the efficacy of this treatment, access 
to it is endorsed by UN bodies, scientific research 
bodies, and many governments around the world.67 
Beyond combating the spread of HIV and hepatitis 
C infection, when OST has been implemented to 
scale, reductions in overdose, drug-related deaths, 
and crime can be observed.68 Moreover, it has 
been shown to be a critical component in increased 
adherence to antiretroviral therapy and tuberculosis 
treatment,69 while the benefit return for OST is 
estimated to be four times the treatment cost70; 
according to the National Institute on Drug Abuse in 
the United States, methadone treatment is “among the 
most cost-effective treatments, yielding savings of $3 
to $4 for every dollar spent.”71 
Despite the overwhelming evidence in support of 
OST, global coverage is extremely low, with the 
treatment only available in around half of the countries 
reporting injecting drug use. What is more, this global 
snapshot does not capture the quality of national-level 
coverage of OST; in some countries OST is available 
only within the context of detox or rehabilitation 
facilities, and adequate provision is typically 
concentrated in high-income countries, replicating the 
scenario seen with inequitable access to controlled 
medicines for pain relief. 
In many countries OST coverage levels fall far below 
the levels recommended by international guidance73; 
for example, in Asia, five countries—Afghanistan, 
India, Myanmar, Sri Lanka and Vietnam—report 
coverage levels of less than 20 percent, very low by 
international guidance standards. 
“The existence of national policy on harm reduction [including OST] does not 
inevitably equate to provision of an adequate response in either scope or quality.”72
Harm Reduction International, 2014 
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The Success of Heroin-Assisted Treatment in Switzerland
In 1988, 74 percent of the Swiss population named illicit drugs as the second-
most pressing problem in the country. As a reaction to the open drug scenes, 
Switzerland conducted a scientific study on the medical prescription of heroin 
(today known as heroin-assisted treatment or HAT) with the aim of assessing:
• the suitability of this treatment method for people suffering from heroin 
addiction who had been failed by other treatments, and;
• the impact of such treatment on health and social outcomes. 
Consequently, patients should become healthier, return to work, refrain from 
consumption of nonprescribed substances, and abstain from delinquency. 
In response to the International Narcotic Control Board’s (INCB) 
recommendations, Switzerland requested WHO to set up a group 
of independent international experts for evaluation. 
The main conclusions of the abovementioned study and evaluation were:
• Health: Meaningful improvements in patients’ health status and high 
retention rates in HAT are among the most striking results. 
• Public safety and security: Significant positive changes regarding 
employment and criminal behavior were achieved. The evaluation 
showed an overall drop of 68 percent in contacts with police. 
• Cost-effectiveness: Benefits overcompensate the costs of HAT with clear 
return on investment in the area of legal behavior (i.e., decrease of days 
of imprisonment, and improved health status of participants). 
In 1998 HAT became available as a regular but restricted 
treatment with the following admission criteria:
• minimum age of 18 years;
• at least two years of opiate addiction;
• at least two unsuccessful treatment attempts; 
• medical, psychological, or social deficiencies caused by the addiction. 
In a nationwide referendum, HAT was confirmed by the majority 
(54.4 percent) of the Swiss electorate in 1999. 
In 2008, after another nationwide referendum, the Swiss electorate 
accepted—with a majority of 68.1 percent—to anchor HAT as a 
treatment option into the Swiss federal law on narcotic drugs.
Source: Diane Steber Büchli, Swiss Federal Office of Public Health
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A key contributor to this lack of access is the 
stigmatizing environment created by the drug 
treaty regime, which, as stated above, emphasizes 
the need to suppress “addiction,” described in the 
Single Convention’s preamble as a “serious evil” that 
States have a “duty to prevent and combat.”74 This 
fear of addiction, and the resultant stigmatization of 
people who use drugs, has led to an overreliance on 
regulatory models at the domestic level that prioritize 
the prevention of diversion rather than ensuring 
access to OST. Indeed, some countries have tended 
to create a “hierarchy” among patients in need of 
controlled medicines, prioritizing those with cancer 
pain over patients with opioid dependence—the 
latter being seen as blameworthy, suspicious, and less 
deserving of pharmacological treatment. 
Even in the scenario where access to OST is 
permitted, people using these services may still face 
the threat of police harassment or arrest around 
treatment centers and therefore stop engaging with 
OST programs. For some groups such as women 
and young people, additional barriers have been 
reported such as age restrictions,75 a lack of gender-
sensitive services, and a fear of loss of legal custody of 
children.76 
As with access to controlled medicines for pain 
relief, weak healthcare systems significantly impact 
the availability of OST. This is exacerbated by a lack 
of dedicated funding for these services, leading 
to a situation where it is estimated that USD $160 
million, or just 7 percent of what is required, is 
currently invested in harm reduction programs 
globally. Given that this estimate includes additional 
elements of comprehensive harm reduction package 
interventions,77 the total amount invested in OST 
alone is likely to be far lower than this.  Conversely 
around USD $100 billion is invested in punitive 
responses to drugs.78 A rebalancing of spending 
whereby there is a concrete move away from law 
enforcement and toward a public health approach is 
thus vital.
The INCB has rarely—if ever—criticized States 
for failing to ensure proper medical access to OST, 
despite the clear obligation to do so under both 
international drug control and human rights law.79  
The INCB, along with UNODC, should play a key 
role in ensuring States provide access to an adequate 
supply of OST for medical purposes as, to date, the 
INCB’s enthusiasm for this element of their mandate 
has been lukewarm at best.
FIGURE 3:
GLOBAL AVAILABILITY OF OPIOID SUBSTITUTION THERAPY IN THE COMMUNITY AND IN PRISONS
Source: HRI
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Under the current framework 
UN drug control bodies must 
take a more balanced, proactive, 
and coordinated role in helping 
countries ensure access 
to controlled medicines
For decades the INCB has been perceived as being 
overly concerned with any potential weakening 
of the international drug control system, and until 
recently has often been silent on human rights 
abuses committed in the name of drug control,80 thus 
contributing to the current situation in relation to 
access to controlled medicines.
Its refusal to criticize countries like Russia, whose 
human rights abuses of people who use drugs are 
evident, is just one example. Russia actively prohibits 
OST, which, along with the absence of needle and 
syringe programs, has led to a situation where the 
number of HIV cases in the country increased 80 
percent between 2004 and 2014.81 Within the next 
five years, 3 million people in the country could 
be HIV positive.82 The INCB’s silence is a failure 
to acknowledge a significant breach of the right to 
health recognized in international human rights law—
including in the ICESCR, which Russia has ratified and 
hence pledged to uphold. 
There are mechanisms to address these issues; Article 
14 of the Single Convention enables the INCB to: 
initiate a process of consultation; require explanations; 
and provide recommendations to States Parties to 
adapt their policies if the “aims of this Convention are 
being seriously endangered by reason of the failure 
of any Party, country, or territory to carry out the 
provisions of this Convention.”83 
Yet, the INCB has never used this mechanism to 
address any country’s failure to provide adequate 
estimates, or outright refusal to ensure access to 
controlled medicines for their population. The INCB 
should invoke Article 14 in conjunction with Article 
14 bis, which would provide technical and financial 
assistance to countries that have repeatedly failed to 
meet their obligation under international law.84
What is more, the INCB should recognize the 
important role it can play in highlighting human 
rights abuses as part of the international drug control 
system, including, but not limited to, the failure to 
provide controlled medicines. 
The UNODC, which has more resources than INCB 
and in-country or regional staff on the ground, could 
arguably play a more active role in helping scale-
up access to controlled medicines by providing 
technical support for countries to help them assess 
whether their domestic laws impede access. While 
it is currently difficult to assess existing levels of 
Where Conflict Hinders Access: The Scaling Back of OST in Eastern Ukraine
The delivery of controlled medicines to Donbass, Ukraine, became more difficult due to 
security restrictions and regulatory controls established by the Presidential Decree of 
November 2014 (n°875) on “urgent measures to stabilize the socioeconomic situation 
in Donetsk and Luhansk regions.” The government has cut funding to all health facilities 
(including staff salaries) that have remained in the Non-Government Controlled-
Area (NGCA) territory for fear that national budget funds would fall into the hands 
of the armed groups. Methadone and buprenorphine, in particular, were considered 
as “narcotic medicines” and “potential weapons,” and therefore subjected to specific 
and complex regulatory procedures. Despite the repeated efforts of the international 
community, including the suggestion made by Médecins Sans Frontières in Donetsk 
to monitor the distribution and utilization of methadone to address concerns from the 
Government of Ukraine, these medications were not allowed to be delivered by UN 
Humanitarian Convoys. Based on data collected by the International HIV/AIDS Alliance 
in Ukraine, as of July 2015, over 1,000 patients residing in Donbass had lost access to 
OST due to a lack of medical supplies and the closure of OST administering sites.
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support on this issue, anecdotal evidence suggests 
that resources—human, technical, and economic—
disproportionately focus on building the capacity of 
law enforcement agencies in relation to interdiction.  
In light of this, UNODC should provide transparent 
data on what field operations are focused on and 
where resources are positioned. Furthermore, the 
UNODC, which houses the secretariat to CND, 
should ensure that resources are deployed to support 
countries to meet all of their obligations under the 
drug control treaties and international human rights 
law. 
The INCB and UNODC must ensure that they are 
fulfilling the requirements of their mandates and that 
their work focuses equally on preventing diversion 
and ensuring access to controlled medicines, while 
adhering to international human rights obligations. 
This has to be central to all aspects of their work, in 
all arenas including in-country or regional UNODC 
offices. Both bodies, in collaboration with WHO, must 
implement a balanced, proactive, and coordinated 
approach to ensuring access to controlled medicines. 
Governments should fund a 
renewed international program 
led by WHO to ensure equitable 
access to controlled medicines.
WHO’s clear acknowledgement of the need to work 
toward a more balanced model for ensuring access, 
in conjunction with its stated belief that drug control 
should be used to optimize public health, underscores 
the necessity for its involvement on the issue. 
Indeed, over the past decade its role has expanded 
with the launch in 2007 of the Access to Controlled 
Medicines Program (ACMP), a joint initiative with 
the INCB aimed at providing technical assistance to 
governments in identifying and removing key barriers 
to access.
However, while the ACMP was instrumental in a 
number of key developments—notably developing 
the aforementioned WHO Policy Guidelines for 
Controlled Substances and WHO/INCB Guide on 
Estimating Requirements for Substances Under 
International Control—its work has been severely 
hindered by a lack of funding in recent years. Since 
2008, WHO has been unable to fund the program 
itself, and though interim funding was provided by 
the European Commission and Dutch Government, 
the ACMP’s work has effectively ground to a halt in 
recent years.
The Global Commission reiterates the 
recommendation of its 2014 report, “Taking Control: 
Pathways to Drug Policies That Work,” that WHO, in 
cooperation with UNODC and INCB, take the lead in 
ensuring access to controlled medicines. 
Currently, WHO does not have the resources or 
manpower to oversee a new international initiative; 
this must be addressed as a matter of urgency with 
a view toward scaling up the agency’s capacity to 
ensure access to controlled medicines. Governments 
need to commit funds and establish a clear plan with 
timelines outlining specific goals, which would see the 
removal of domestic and international obstacles to 
provision. This could include regional WHO/UNODC 
offices assisting national governments’ move towards 
a public health approach that addresses all obstacles 
in ensuring access for controlled medicines.
“Drug control should not be approached as an objective in itself, but as a tool to 
optimize public health. One focus should be the prevention of abuse and dependence; 
the other to avoid collateral harm. The outcomes should be judged both by the harms 
from abuse it prevents and the harms it cause through, for example, lack of access.” 
WHO, 201185
22GLOBAL COMMISSION ON DRUG POLICY:  Drug Control’s Negative Impact on Public Health: The Global Crisis of Avoidable Pain
UN drug conventions contribute to the limitations in research into 
the potential medical benefits of other controlled substances
LSD, MDMA, cathinone, and psilocybin are all substances that are subject to 
the strictest control under the 1971 Convention on Psychotropic Substances. 
Under Schedule I they are deemed to present “a high risk of abuse, posing a 
particularly serious threat to public health with little or no therapeutic value.”93 
This is reflected in many countries whose domestic laws deem these substances to have 
no therapeutic effect. As such, research is limited by regulatory hurdles, and makes them 
extremely expensive to buy in medical-grade form. For example, UK regulations permit 
hospitals to have a license for Schedule II substances—morphine, cocaine etc.—but those 
wishing to research Schedule I substances have to obtain a Home Office license94; a 2013 
study highlighted that only three out of thousands of hospitals in the UK had such a license.95 
This experience is not limited to the UK; it took researchers in Canada four years 
to import MDMA from Switzerland for a study looking at its therapeutic use for 
PTSD.96 In addition to the regulatory restrictions, the cost of these substances 
makes them prohibitive for research purposes. For example, one company 
supplying a gram of psilocybin was charging US$12,000 per gram.97
The medicinal benefits of these substances are starting to come to light as a 
result of minimal but groundbreaking research. Studies have explored the use 
of MDMA to assist psychotherapy, with one study in the US conducted in 
relation to patients suffering from “treatment-resistant PTSD.”98 The results were 
impressive, with 80 percent of patients showing clinical benefits compared to 
only 20 percent in the control group.99 Other potential conditions where MDMA 
could have a positive effect include autism and Parkinson’s disease.100
Photo: Nyeri Hospice, part of KEHPCA, Kenya Hospices and Palliative Care Association. 
© Sven Torfinn for the Open Society Foundations
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The international drug 
control system contributes 
to the criminalization of 
people who use cannabis 
for medicinal purposes 
Millions use cannabis for medicinal purposes globally, 
and, although not a controlled medicine, it has been 
synthesized by pharmaceutical companies for medical 
use. These pharmaceutical products have seen 
many domestic legislators stretch the law in relation 
to cannabis, with the products themselves being 
controlled as a class of substance that is distinct. In 
a large number of countries cannabis is scheduled 
as having “no therapeutic effect,”86 a result of its 
scheduling under the Single Convention. 
The Single Convention categorizes substances across 
three schedules,87 which, based on risk of harm and/
or misuse and therapeutic value, would be subject 
to varying degrees of control. Schedule I contains 
substances considered to be “highly addictive and 
liable to abuse”88 and are subject to “all [emphasis 
added] measures of control applicable to drugs under 
this Convention.”89 Additionally, some substances that 
are controlled in Schedule I are included in Schedule 
IV where they are considered to be “particularly 
dangerous”90 and are thought to have “little, or no 
therapeutic value.”91 Cannabis is both a Schedule I 
and Schedule IV substance.
Cannabis has significant value for its potential to 
treat a range of medical conditions. Researchers 
have suggested that various active ingredients in 
the substance could be beneficial for a number 
of conditions including: pain, spasticity (Multiple 
Sclerosis [MS]), anxiety disorders, seizure disorders 
including epilepsy, psychosis, addiction, post-
traumatic stress disorder (PTSD), and attention-deficit 
hyperactivity disorder (ADHD).92
Many users of cannabis for medicinal purposes 
confirm that it is effective at reducing their pain and 
significantly alleviates the symptoms of conditions 
like MS and epilepsy. While some are able to access 
pharmaceutical cannabis-based medication, the vast 
majority of those medicating themselves have no 
choice but to risk criminalization, either by growing 
their own plants or purchasing it from the illicit 
market. It is a tragedy that people who are in need 
of medication have to risk imprisonment in order to 
alleviate their suffering.
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